All AstraZeneca articles
-
OpinionIs UK pharma really ‘uninvestable’?
Merck & Co, AstraZeneca (AZ) and Eli Lilly pulling UK projects highlights the precarious position of the country’s life sciences industry
-
BusinessUK loses life sciences investment as pharma companies halt expansion plans
Industry seeks greater share of healthcare spending to support innovation
-
BusinessRevolutionising RSV prevention
New vaccines and a long-acting antibody aim to protect older adults and babies from respiratory syncytial virus
-
CareersThe many career benefits of apprenticeships
On-the-job training combined with a qualification provides apprentices with a solid first step on the scientific career ladder
-
BusinessPharmaceuticals roundup 2021
It’s been another dramatic, pandemic-dominated year for the pharmaceutical industry
-
BusinessUS grants Pfizer’s Covid-19 vaccine full approval
WHO calls for delay to booster programmes to allow more global distribution
-
BusinessRegeneron’s Covid-19 antibodies help those who can’t make their own
Regn-Cov2 reduces deaths and shortens hospitalisation for these patients, even when given at late stages of infection
-
BusinessCovid vaccination efforts bolstered by trial results from J&J and Novavax
A miserable January ended with positive news on the vaccine front but new variants added complications
-
BusinessAstraZeneca to buy rare disease drugmaker Alexion in $39bn deal
Transaction would be the largest in AstraZeneca’s history
-
BusinessPfizer–BioNTech vaccine gains emergency approvals in US, Canada and beyond
UK begins vaccinating vulnerable populations after early authorisation
-
BusinessUK grants Pfizer–BioNTech Covid-19 vaccine emergency approval
Regulators around the world working towards accelerated decisions on vaccine data
-
-
BusinessOxford–AstraZeneca vaccine joins others with promising interim data
Cheap and fridge-stable candidate at least 60% and up to 90% effective at preventing disease
-
BusinessEncouraging signs from initial Covid-19 vaccine trials
Human trials deliver positive immune responses, while primate challenge studies suggest protection is possible
-
CareersHarnessing the power: AstraZeneca apprentices
How an AstraZeneca apprentice solved the business-wide problem of drug compound solubility
-
CareersSix years of AstraZeneca’s graduate training programme
The participants in the scheme are finding success in a variety of careers
-
WebinarHow to ensure Quality by Design
Learn how to develop consistently better processes with a strategic focus on risk, understanding and control
-
BusinessPharmaceuticals roundup 2018
Merger deals, product approvals and infrastructure changes have been overshadowed by political uncertainty, in Europe and around the world
-
BusinessNovartis exit from antibiotics a setback for race against resistance
Experts say business models must change to halt big pharma exodus
-
BusinessTakeda tightens focus on core areas with multiple deals
Japanese firm is remodelling its R&D efforts through collaboration and licensing deals, and selling off non-core businesses